Figure 3.

Percentage of patients treated with placebo, infliximab, or placebo followed by infliximab responding to therapy in the double-blind and open-label phases of the study. The results are from an intention-to-treat analysis. Reproduced with permission from John Wiley & Sons, Inc. [56]. © 2002 American College of Rheumatology

Peloso and Braun Arthritis Res Ther 2004 6(Suppl 2):S36-S43   doi:10.1186/ar1012